UroGen Pharma Ltd.

UroGen Pharma, Inc. is a biotechnology company focused on developing and selling new treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel reverse-thermal hydrogel technology, which is designed to improve how existing drugs work by allowing them to stay in contact with urinary tract tissue for longer periods. This technology aims to make local therapy more effective. UroGen Pharma has two approved products: Jelmyto (mitomycin) for pyelocalyceal solution, which treats low-grade upper tract urothelial cancer, and Zusduri (mitomycin) for intravesical solution, which treats recurrent low-grade intermediate risk non-muscle invasive bladder cancer. Both products are designed to remove tumors without surgery. The company's development pipeline also includes UGN-501 (formerly ICVB-1042), an investigational oncolytic virus for immuno-uro-oncology. RTGel is a biocompatible, polymer-based hydrogel that is liquid at lower temperatures and turns into a gel at body temperature. This property facilitates easy delivery and retention of drugs in body cavities like the bladder and upper urinary tract, creating a temporary drug reservoir that dissolves over time, preventing rapid excretion, and increasing dwell time. RTGel's inactive polymer components are used in Jelmyto and Zusduri, formulated with the active drug mitomycin. These formulations are instilled as a liquid via catheters or nephrostomy tubes, gel at body temperature, and then gradually dissolve upon contact with urine, releasing the active drug over several hours, with less impact from urine production and voiding cycles compared to water formulations.